Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8119650 | 1.00 | SIGMAR1 (0.53) | SIGMAR1KCNA5CA12CA7CA9 | |
| SCHEMBL20577929 | 1.00 | SIGMAR1 (0.53) | SIGMAR1KCNA5CA12CA7CA9 | |
| SCHEMBL4848433 | 0.87 | KCNA5 (0.50) | KCNA5CA12CA7CA9CA14 | |
| SCHEMBL17695118 | 0.86 | SIGMAR1 (0.49) | SIGMAR1APAF1KMT2AMEN1ALDH1A1 | |
| SCHEMBL21209154 | 0.86 | SIGMAR1 (0.49) | SIGMAR1APAF1KMT2AMEN1ALDH1A1 | |
| SCHEMBL13674818 | 0.86 | POLB (0.49) | SIGMAR1KCNA5CA12CA7CA9 | |
| SCHEMBL4858585 | 0.85 | KCNA5 (0.49) | SIGMAR1KCNA5CA12CA7CA9 | |
| SCHEMBL4856680 | 0.84 | KCNA5 (0.46) | SIGMAR1KCNA5CA12CA7CA9 | |
| SCHEMBL21193183 | 0.84 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3KMT2AMEN1 | |
| SCHEMBL4884782 | 0.84 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412665-B1 | SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412665-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-7449325-B2 | Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof | UBE INDUSTRIES, LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1493819-A1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | Ube Industries, Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | CYP8B1, SRR, HM13 | SIGMAR1 1339/4885KCNA5 4185/4885CA12 2508/4885 |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | COMT, KMO, CYP4B1 | SIGMAR1 271/4885KCNA5 512/4885CA12 3344/4885 |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | COMT, KMO, CYP4B1 | SIGMAR1 271/4885KCNA5 512/4885CA12 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.